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Non-Hodgkin’s Lymphomas
Anaplastic large cell lymphomas are peripheral T-cell lymphomas that are characterized by a proliferation of large
anaplastic blasts expressing CD30. In children, systemic anaplastic large cell lymphomas often present at advanced
clinical stage and harbor translocations involving the anaplastic lymphoma kinase (ALK) gene leading to the
expression of chimeric anaplastic lymphoma kinase (ALK)-fusion proteins. Primary cutaneous anaplastic large cell
lymphoma is regarded as an ALK-negative variant confined to the skin and is part of the spectrum of primary cuta-
neous CD30-positive T-cell lymphoproliferative disorders. Thirty-three of 487 pediatric patients registered within
the Anaplastic Large Cell Lymphoma-99 trial (1999 to 2006) presented with a skin limited CD30-positive lympho-
proliferative disorder. In 23 of the 33 patients, material for international histopathological review was available,
and the cases were studied for histopathological, immunophenotypical and clinical features as well as for breaks
within the ALK gene. Five of 23 cases and one additional case (identified after closure of the trial) expressed ALK-
protein. Complete staging excluded any other organ involvement in all children. Expression of ALK proteins was
demonstrated by immunohistochemistry in all cases and the presence of breaks of the ALK gene was genetically
confirmed in 5 evaluable cases. The histopathological and clinical picture of these skin-restricted ALK-positive
lymphomas was indistinguishable from that of cutaneous anaplastic large cell lymphoma. Five children presented
with a single skin lesion that was completely resected in 4 and incompletely resected in one. Three of these
patients received no further therapy, 2 additional local radiotherapy, and one chemotherapy. All children remain
in complete remission with a median follow up of seven years (range 1-8 years). We present 6 pediatric cases of
ALK-positive primary cutaneous anaplastic large cell lymphomas. After thorough exclusion of systemic involve-
ment, therapy confined to local measures seems to be sufficient to induce cure. 
©2013 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2012.065664
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Introduction
Anaplastic lymphoma kinase-positive (ALK-positive)
anaplastic large cell lymphoma (ALCL) is characterized by a
neoplastic proliferation of large pleomorphic (anaplastic) CD30-
positive (CD30+) T cells with typical translocations involving
the ALK gene and subsequent expression of chimeric ALK pro-
tein.1 This lymphoma accounts for approximately 15% of
childhood non-Hodgkin’s lymphomas, but is rare in adult-
hood.2,3 ALK-positive (ALK+) ALCL is usually a systemic disease
that frequently involves extranodal sites. In children, 18-25%
of systemic ALCLs develop skin manifestations during the
course of the disease and this is a poor prognostic factor.4-9
Systemic ALK-negative (ALK-) ALCL is included in the updated
WHO classification as a separate preliminary entity.1 ALK-neg-
ative ALCL accounts for less than 5% of pediatric systemic
ALCLs.5,10 However, both ALK-positive and ALK-negative
ALCLs are considered potentially disseminated diseases.1
Primary cutaneous ALCL (cALCL) is regarded by the WHO
as a separate disease entity and belongs to the spectrum of
primary cutaneous CD30-positive lymphoproliferations
(CD30+LPD), a group that also includes lymphomatoid
papulosis (LyP).1 CD30+ LPDs share with systemic ALCL
the presence of neoplastic CD30+ large T cells, but lack
ALK translocations and protein expression. cALCLs
remain confined to the skin, virtually never disseminate
beyond local lymph nodes, and show an excellent progno-
sis after surgical resection without systemic therapy. Most
cases of cALCL present as solitary skin lesions, but multi-
ple skin nodules are also found. In contrast to systemic
ALCL, cALCL is only rarely found in children and young
adults.11-13 Recently published recommendations for the
diagnosis of CD30+LPD state that immunohistochemical
detection of ALK expression should be considered highly
suspicious of a cutaneous manifestation of underlying sys-
temic ALCL.13 In contrast, IRF4 translocations have been
reported in cALCL and in ALK- ALCLs but not in ALK+
ALCL.14,15 In the international multicenter trial ALCL99,
children included with localized skin disease were not to
receive systemic chemotherapy based on the assumption
that their disease would be CD30+LPD. We describe a
series of 6 pediatric ALCLs that clinically and histological-
ly resembled cALCL but expressed ALK fusion proteins.
These localized cutaneous ALK+ ALCL followed the typi-
cal benign clinical course of a CD30+LPD.
Design and Methods
Identification of cases and histopathological review
In the ALCL99 multicenter study, 487 children and young adults
with the diagnosis of ALCL were registered from 1999 to 2006,
including 33 patients with a CD30+ lymphoproliferative disorder
limited to the skin. Patients with isolated skin lesions diagnosed
by complete staging procedures were to be followed after resec-
tion by ‘watchful waiting’ without further systemic therapy
regardless of the Alk status. For 23 of these, skin limited lym-
phoma material was available for an international histopathologi-
cal review. One additional case reported here was identified after
completion of registration in 2006. The histological review of the
cases was performed by members of the international pediatric
lymphoma pathology panel  (IO, LL, AN, EdA, UH, KH, ISK, JM,
LM, MT) using hematoxylin and eosin (H&E) stained slides as well
as slides stained immunohistochemically in various laboratories
(see below). The registered clinical data from the study center were
reviewed and additional details were obtained by contacting the
attending pediatric oncologist. The study was part of the scientific
projects accompanying the ALCL99 study, for which informed
consent was obtained. The study was carried out according to the
local ethical guidelines and in accordance with the ethical guide-
lines of the studies in which the patients were treated.
Immunohistochemistry and fluorescence
in situ hybridization
All immunohistochemical stainings were performed on whole
tissue sections. The stainings were scored semiquantitatively as
negative, weak (<30% positive tumor cells or all tumor cells weak-
ly positive), positive (>30% positive tumor cells) or not inter-
pretable. The minimal staining panel for each lymphoma included
CD20, CD3, CD30, and ALK. Additional stainings for granzyme
B, perforin, TIA1, EMA, CD2, and CD5 were available for individ-
ual cases. Due to the retrospective nature of the study, the staining
procedures and antibody sources for these markers varied
between the participating countries but had been previously
established within the group as part of the ALCL99 study.16
Fluorescence in situ hybridization (FISH) for chromosomal breaks
in the ALK gene or at the IRF4/DUSP22 locus was performed as
previously described.17,18 
Results
Identification of the 6 ALK-positive cases limited 
to the skin
Among the 23 cases with ALCL or CD30+ lymphoprolif-
erations confined to the skin registered into the ALCL99
study and available for international histopathological
review, 5 patients with expression of ALK protein were
identified. During the preparation of the manuscript,
another case of ALK+ ALCL limited to the skin was identi-
fied by the NHL-BFM study center and included in this
series.
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Table 1. Histopathological and immunohistochemical features of 6 pediatric cases of ALK-positive primary cutaneous anaplastic large cell lym-
phoma.
Histolopathological features Immunohistochemistry
Case Epidermal Epidermotropism Dermal Involvement of Admixed CD30 ALK ALK ALK+ EMA CD3
n. change of tumor cells involvement* subcutis inflammatory (pattern) staining small cell 
cells pattern component
1 hyperplastic, + + ni – ++ ++ n+cyt + ++ –
ulceration (sheets)
2 ni ni ni + neutrophils ++ ++ n+cyt – ni –
(sheets)
3 normal – + + lymphohistiocytic + + n+cyt + ++ +
(single)
4 normal – + + – ++ ++ n+cyt + ++ –
(sheets)
5 hyperplastic + + + – ++ ++ cyt – ++ –
(sheets)
6 hyperplastic – + + lymphohistiocytic ++ ++ n+cyt + ++ +
(sheets)
Scoring of histopathological features: +: present; -: absent; ni: not interpretable. Scoring of immunohistochemistry: -: negative staining; +: weak staining or <30% of cells moderate to
strong staining; ++: moderate to strong staining in >30% cells; n+cyt: nuclear and cytoplasmic staining; cyt: cytoplasmic staining only. *In all evaluable cases dermal involvement
was superficial and deep.
Histological and immunohistochemical features
The main histological and immunohistochemical fea-
tures of the 6 cases are summarized in Table 1. In most
cases, a superficial and deep cutaneous infiltration extend-
ing into the subcutis was observed (3 of 4 cases in which
all skin layers were included in the biopsy specimen). The
lesions were rather poorly demarcated. In one case, an iso-
lated subcutaneous nodule without dermal involvement
was seen. In 5 cases, the epidermis was included in the
specimen and was either normal in appearance (n=2),
showed hyperplastic changes (n=2), or hyperplastic
changes with additional focal superficial erosion (n=1). A
large number of CD30+ neoplastic blasts forming cohesive
sheets were detectable in 5 of 6 cases. However, one case
displayed only scattered blasts. In 3 of 6 lesions, the
growth pattern of the blasts was perivascular. Reactive
inflammatory bystander cells were composed of a moder-
ate number of neutrophils (1 of 6) or lymphohistiocytic
cells (2 of 6). No inflammatory bystander cells were
detectable in 3 of 6 lymphomas. Figure 1 shows one rep-
resentative example of an ALK+ ALCL confined to the
skin.
ALK expression was immunohistochemically detectable
in all cases with nuclear and cytoplasmic staining in 5 of 6
cases, indicating an underlying NPM-ALK fusion due to a
t(2;5) translocation. In one lymphoma, diffuse cytoplasmic
ALK staining without nuclear positivity was noted.
Interestingly, in 4 of 6 lymphomas, a small cell component
was detectable, as indicated by predominately nuclear
staining of small lymphoma cells (Figure 2). All 5 cases
tested for epithelial membrane antigen (EMA) were
strongly positive. CD3 was negative (4 of 6) or weakly
expressed (2 of 6). All lymphomas expressed at least one
cytotoxic protein, such as granzyme B, TIA1 or perforin
with the characteristic granular staining pattern (data not
shown).  
Fluorescence in situ hybridization
Material for fluorescence in situ hybridization was avail-
able for 4 lymphomas. Breaks in the ALK gene were
detectable in all 4 analyzed cases (Figure 1). In the addi-
tional patient with multilocular skin disease NPM-ALK-
transcripts were detected in the bone marrow and blood
by polymerase chain reaction (data not shown) so that the
ALK-translocation was confirmed molecularely in 5 of 6
patients. In contrast, breaks affecting the IRF4/DUSP22
locus in 6p25 recurrently involved in cALCL were not
detectable in the 3 cases studied. 
Clinical characteristics, therapy and outcome
Table 2 summarizes the clinical characteristics of the
patients reported in this series. Median age was 10.8 years
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Figure 1. Clinical and histological features of one rep-
resentative example of ALK-positive ALCL confined to
the skin (case 6, see Tables 1 and 2). This is a nodular
lesion on the thigh, approximately 2 cm in largest
diameter (case 6). The black ink marks the area that
had initially been planned for resection; it was later
decided to resect the lesion completely (A). At low
magnification deep extension of the lesion with a
dense dermal infiltration as well as reactive epidermal
hyperplasia is observed (B) (Hematoxylin & Eosin stain-
ing). Cytologically, histiocytes, a few lymphocytes and
intermingled atypical large cells are seen (C)
(Hematoxylin & Eosin staining). Large cells in clusters
with a perivascular pattern are observed. There is no
epidermotropism (D, CD30). Large cells show nuclear
and cytoplasmic ALK staining; intermingled with some
smaller cells with nuclear ALK (E, ALK). Fluorescence in
situ hybridization using the LSI ALK BAP probe (Abbott)
indicates a chromosomal breakpoint in the ALK gene
(arrows)(F).
A B
C D
E F
(range 7.5-13.8 years). Three patients were male and 3
female. None of the children had a clinically documented
history of lymphomatoid papulosis (LyP) or mycosis fun-
goides. The lymphomas presented clinically as papulo-
nodular skin lesions (5 of 6) and/or subcutaneous nodules
(3 of 6). One patient displayed multiple skin lesions (case
4) which were described as multiple pink nodules on the
trunk, arms and neck. The isolated lesions in the other 5
patients involved the thigh (n=3), neck (n=1) or knee
(n=1). Figure 1 shows the clinical presentation of one case
with a solitary lesion on the thigh (case 6). None of the
children suffered from B symptoms. All patients under-
went a complete initial staging procedure to exclude sys-
temic disease according to the ALCL99 protocol, including
imaging of the abdomen and thorax, full blood cell count
and bone marrow cytology. Lumbar puncture was per-
formed in 5 of the 6 patients. In one patient, minimal dis-
seminated disease (MDD) was detectable, measured by
polymerase chain reaction for NPM-ALK transcripts19 in
the bone marrow and blood (case 4, Table 2 and data not
shown). The single skin lesion was surgically completely
resected in 4 of the 5 patients. One patient received addi-
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Table 2. Clinical features of 6 pediatric cases of ALK-positive primary cutaneous anaplastic large cell lymphoma.
Clinical characteristics at diagnosis Therapy Outcome
Case n. Age Maculopapular Subcutaneous Multiple Location B symptoms Staging* Complete Chemo/ Relapse Follow up 
(years) lesions nodules skin resection radiation (years)
lesions
1 9.1 + – – ventral thigh, – + + – - 8
approx. 2 cm 
in  diameter
2 7.5 + + – neck, – + + – - 2.3
approx. 3 cm 
in diameter
3 10 + – – thigh, n.e. + + – - 8
small red lesion
4 11 + + + anterior wall – + (MDD+ – chemo2 - 8
of thorax, neck, arms, BM and pB)1
back: pink nodules
5 11.9 – + – right knee – + – radiation - 5.2
6 13.8 + – – left thigh – + (no CSF) + radiation - 1
1MDD: minimal disseminated disease assessed by RT-PCR for t(2;5) (NPM;ALK) in the bone marrow (BM) and peripheral blood (pB) was positive; 2chemotherapy according to
ALCL99 was pre-phase, 3xA, 3xB, complete remission after A1. CSF: cerebrospinal fluid; n.e.: not evaluated; staging*: +: complete clinical staging was performed and remained neg-
ative.
Figure 2. An example of ALK-positive ALCL (case 1,
see Table 1) with epidermotropism of lymphoma
cells and a subepithelial small cell tumor compo-
nent. (A and B) Hematoxylin & Eosin staining. (C)
ALK1). 
A
B C
tional local radiotherapy after complete excision and in
one case an incomplete resection of the skin lesion was
followed by local radiotherapy. The patient with multiple
skin nodules and MDD in the bone marrow and peripher-
al blood (case 4, Table 1) received 6 courses of chemother-
apy according to the protocol ALCL99 in the high-risk
arm.20 None of the other patients received chemotherapy.
All patients reached a complete remission and remained
disease-free with a median follow up of seven years (range
1-8 years). 
Discussion
We report here 6 cases of ALK+ ALCL limited to the
skin. These lymphomas mimicked primary cutaneous
CD30+LPD in their histopathology, clinical presentation
and response to therapy. 
CD30+LPD comprise a spectrum of diseases confined to
the skin, including LyP and cALCL, which show overlap-
ping histological features. Both diseases are characterized
by a neoplastic infiltrate of anaplastic CD30+ T cells with
a variable admixture of reactive inflammatory cells. Single
nodular skin lesion or, less frequently, multiple nodules
that do not undergo spontaneous regression are the typical
presentation of cALCL.1,13 Distinguishing a primary cuta-
neous CD30+LPD, such as LyP and cALCL, from second-
ary involvement of the skin by systemic ALCL is clinically
relevant. Treatment of systemic ALCL consists of risk-
adapted polychemotherapy. Secondary skin involvement
is regarded as a clinical risk factor, often utilized to stratify
patients to a more aggressive treatment regimen.21,22 In
contrast, primary cutaneous CD30+LPD, which is limited
to the skin and rarely disseminates, usually either resolves
spontaneously or is treated locally, e.g. by surgical exci-
sion.13
All of our cases fulfilled the clinical and histological cri-
teria of a primary cutaneous anaplastic large cell lym-
phoma with predominantly solitary skin lesions, no histo-
ry of LyP, no extracutaneous dissemination and response
to local therapy,13 but all cases were ALK+. Given the high-
er incidence of cALCL in adults, most published series
analyzing ALK expression have included predominately
adult patients.23 There have been only single case reports
and small series of pediatric cALCL, and in these ALK
staining was inconsistently performed.24-28 We assume that
our series is not population-based as cutaneous CD30+LPD
are diagnosed and treated either by dermatologists or
pediatric oncologists. Nevertheless, our data suggest that
ALK+ cALCL might be more frequent than anticipated
within the pediatric population, and recommend that all
CD30+LPD of the skin in children should be carefully ana-
lyzed for ALK expression. 
Lamant et al.29 recently reported 5 children with sys-
temic ALK+ ALCL that presented as skin lesions at the site
of preceding insect bites, often with involvement of the
draining local lymphnode. Thus, the skin might not only
present a preferred microenvironment for ALK+ ALCL but
might even be the primary site of lymphomagenesis. At
the moment, no reliable histopathological features are
known to distinguish secondary skin involvement by a
systemic ALCL from primary cutaneous CD30+LPD. EMA
has been reported to be positive in most systemic ALK+
and ALK- ALCLs30 but negative in cALCL.13,31 ALK protein
expression, as well as the underlying ALK-gene transloca-
tion, are considered indicative of systemic ALK+ ALCL and
are seen in nearly all pediatric systemic ALCL cases.10,20 In
contrast, cALCL is considered ALK- both at the molecular
and the protein level.32-35 Our cases were ALK and EMA
I. oschlies et al.
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Table 3. Literature review of reported ALK-positive cutaneous anaplastic large cell lymphomas and findings in this series.
Age Gender Localization ALK Therapy Local Distant Number of Treatment of Systemic Outcome Observation
expression of first recurrence cutaneous recurrences recurrent dissemination period
pattern lesion recurrence reported lesions in months
Chan et al.40 33 m multiple: nuclear and 6 cycles of no yes 2 excision, systemic relapse CCR 31
trunk, head, cytoplasmic chemotherapy1 chemotherapy 2 years  after 
leg diagnosis
Kadin et al.36 57 m single cytoplasmic2 surgical no yes 6 surgical no CCR 156
lesion leg excision excision and
radiotherapy
Sasaki et al.37 57 f single cytoplasmic spontaneous no yes several total excision systemic DOD 71
and lesion regression and radiotherapy relapse 2.5
Hosoi et al.39 forehead without years after 
treatment diagnosis,
3 years later 
systemic relapse and 
DOD
Beylot-Barry33 1/26 reported primary nuclear and not not not not not no not at least 6
cutaneous CD30+ cytoplasmic known known known known known known
lymphomas3
Su et al.38 57 f multiple cytoplasmic 6 cycles CHOP4 no no 0 no no CCR 13
lesions: trunk
This series mean 3 m 5 patients: 5 cases with 3 cases: surgical 0/6 0/6 0/6 no no all CCR mean: 65
n=6 age: and single lesions nuclear and excision, (range 12-96)
10.7 3 f at leg or neck; cytoplasmic 2 cases: excision
(range 1 patient: and 1 case with and local radiotherapy, 
7-13) multiple cytoplasmic 1 case chemotherapy
1Cyclophosphamide, vincrestine, prednisolon, hydroxydoxorubicine. 2Molecular findings: phosphorylated cytoplasmic ALK protein; FISH: no ALK break. 3Clinical details were not described. 4Cyclophosphamide,
adriamycine, vincristine, prednisone. CCR: complete clinical remission; DOD: death of disease.
positive on the one hand but localized and limited to the
skin on the other. They, therefore, presented as and thus
could be named as primary cutaneous ALK-positive ALCL.
One could discuss whether the child with multiple skin
lesions and positive MDD should have been classified as
child with systemic type ALCL. Nevertheless, for the
moment, staging is determined by clinical imaging as well
as by the evaluation of bone marrow cytology, and all
these investigations were negative in this child, indicating
isolated skin disease. In practical terms, the child was
treated with systemic chemotherapy despite the isolated
skin involvement, and we would support this treatment
decision, especially since positive MDD has been shown
to be an adverse prognostic factor in systemic ALCL.19 To
the best of our knowledge, skin-confined variants of ALK+
ALCL have previously been published in 5 cases only.
Table 3 shows a summary of the literature33,36-40 and the
cases presented here. However, the published cases differ
from our series in two main points. First, all previously
published cases were adult patients (Table 2). Second, 2 of
5 previously published cases developed systemic disease
years after the initial primary skin disease; a feature that
was absent in our cohort (Table 2). Just recently, at the
joint workshop of the Society for Hematopathology and
the European Association for Hematopathology
(SH/EAHP) on cutaneous lymphomas held in Los Angeles
in October 2011,41 5 new cases of ALK+ ALCLs confined to
the skin were presented as case reports. Four of these
occurred in adults with variable clinical scenarios, ALK-
staining-patterns and histomorphological features, and
only one ALK+ ALCL confined to the skin was described
in a child with a very unusual mycosis fungoides as clinical
and histological presentation. Therefore, more attention
to ALK-staining in cutaneous T-cell lymphoproliferations
seems justified.
Interesting histological features of the lymphomas
reported here were the presence of a small cell component
in 4 of the 6 cases, and a perivascular growth pattern in 3.
The presence of a small cell component and a perivascular
growth pattern have recently been reported to be associ-
ated with a poorer outcome in systemic ALK+ ALCL.16
However, there was no relapse among the 5 patients with
exclusive local therapy reported in our series. This empha-
sizes again that ALK-positive ALCL limited to the skin
may represent a specific subgroup of ALK+ ALCL for
which prognostic parameters established in systemic ALK+
ALCL do not apply.
In summary, our cases illustrate that ALK+ ALCL can
present as a localized skin-limited disease. Localized treat-
ment with careful follow up seems justified after thorough
exclusion of systemic disease in this rare variant.
Understanding the biology of ALK+ ALCLs that are con-
fined to the skin might influence therapy strategies for
ALK+ ALCL also in other locations.
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